The Journal of rheumatology · 2026
Anti-Integrin αvβ6 Autoantibodies as a Biomarker for Ulcerative Colitis in Patients With Axial Spondyloarthritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yau Enoch, Chim Tina, Lim Melissa, Inman Robert D
Аннотация
OBJECTIVE: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) have recently been described as informative biomarkers for ulcerative colitis (UC), demonstrating a high sensitivity and specificity compared to patients without inflammatory bowel disease (IBD). Given the association between axial spondyloarthritis (axSpA) and IBD, we sought to evaluate the potential of anti-αvβ6 as a biomarker in axSpA patients with or without concurrent IBD.
METHODS: Using an established ELISA protocol, we measured anti-αvβ6 levels in sera of patients with (1) axSpA and UC, (2) axSpA and Crohn disease (CD), (3) axSpA alone, and (4) healthy controls (HCs). Anti-αvβ6 absorbance values were compared between patient groups and clinical variables were compared with anti-αvβ6 positivity.
RESULTS: Eighteen patients with axSpA and UC, 29 with CD, 48 with axSpA alone, and 48 HCs were included. Patients with axSpA and UC showed a significant increase in mean absorbance and anti-αvβ6 positivity rate compared with axSpA alone. For the diagnosis of UC among patients with axSpA, anti-αvβ6 had a sensitivity of 55.6% and specificity of 89.6%, and receiver-operating characteristic analysis yielded an area under the curve value of 0.83. Anti-αvβ6 positivity was associated with a family history of IBD in patients with axSpA and UC. Surprisingly, anti-αvβ6-positive patients had decreased mean C-reactive protein and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores compared with anti-αvβ6-negative patients. Examining serial samples, we observed that 3 of 10 anti-αvβ6-positive patients became anti-αvβ6-negative, whereas anti-αvβ6-negative to anti-αvβ6-positive transitions were not observed.
CONCLUSION: Anti-αvβ6 positivity demonstrated potential as a diagnostic test for UC in patients with axSpA, particularly those with a family history of IBD. To our knowledge, this is the first study to date examining anti-αvβ6 in axSpA.
METHODS: Using an established ELISA protocol, we measured anti-αvβ6 levels in sera of patients with (1) axSpA and UC, (2) axSpA and Crohn disease (CD), (3) axSpA alone, and (4) healthy controls (HCs). Anti-αvβ6 absorbance values were compared between patient groups and clinical variables were compared with anti-αvβ6 positivity.
RESULTS: Eighteen patients with axSpA and UC, 29 with CD, 48 with axSpA alone, and 48 HCs were included. Patients with axSpA and UC showed a significant increase in mean absorbance and anti-αvβ6 positivity rate compared with axSpA alone. For the diagnosis of UC among patients with axSpA, anti-αvβ6 had a sensitivity of 55.6% and specificity of 89.6%, and receiver-operating characteristic analysis yielded an area under the curve value of 0.83. Anti-αvβ6 positivity was associated with a family history of IBD in patients with axSpA and UC. Surprisingly, anti-αvβ6-positive patients had decreased mean C-reactive protein and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores compared with anti-αvβ6-negative patients. Examining serial samples, we observed that 3 of 10 anti-αvβ6-positive patients became anti-αvβ6-negative, whereas anti-αvβ6-negative to anti-αvβ6-positive transitions were not observed.
CONCLUSION: Anti-αvβ6 positivity demonstrated potential as a diagnostic test for UC in patients with axSpA, particularly those with a family history of IBD. To our knowledge, this is the first study to date examining anti-αvβ6 in axSpA.